New agents for the treatment of drug-resistant Mycobacterium tuberculosis

Advanced Drug Delivery Reviews

Volumn 102, Issue , 2016, Pages 55-72

  Hoagland, Daniel T ^a,b   Liu, Jiuyu ^a   Lee, Robin B ^a   Lee, Richard E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antibiotic; Antituberculosis; Drug discovery; Tuberculosis

Indexed keywords

ANTIBIOTICS; DIAGNOSIS; DRUG PRODUCTS; TUBES (COMPONENTS);

ANTITUBERCULOSIS; DRUG DISCOVERY; MEDICINAL CHEMISTRY; MULTIDRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRECLINICAL DEVELOPMENT; TUBERCULOSIS; TUBERCULOSIS BACILLUS;

PATIENT TREATMENT;

BEDAQUILINE; BTZ 043; CPZEN 45; DELAMANID; FROPENEM; LEE 1599; PBTZ 169; POSIZOLID; PYRIDOMYCIN; Q 203; SEQ 9; SQ 641; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IN VIVO STUDY; LIFE CYCLE; MEDICINAL CHEMISTRY; MICROENVIRONMENT; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUBERCULOSIS CONTROL; CHEMISTRY; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84973336086     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.026     Document Type: Review

References (134)

1. Comas I., Coscolla M., Luo T., Borrell S., Holt K.E., Kato-Maeda M., Parkhill J., Malla B., Berg S., Thwaites G., Yeboah-Manu D., Bothamley G., Mei J., Wei L., Bentley S., Harris S.R., Niemann S., Diel R., Aseffa A., Gao Q., Young D., Gagneux S. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat. Genet. 2013, 45:1176-1182.
2. WHO WHO Global Tuberculosis Report 2014 2014.
3. Luciani F., Sisson S.A., Jiang H., Francis A.R., Tanaka M.M. The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. 2009, 106:14711-14715.
4. Udwadia Z.F., Amale R.A., Ajbani K.K., Rodrigues C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 2012, 54:579-581.
5. Zumla A., Nahid P., Cole S.T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 2013, 12:388-404.
6. Drobniewski F. Is death inevitable with multiresistant TB plus HIV infection. Lancet 1997, 349:71-73.
7. Breen R.A.M. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 2006, 66:2299-2308.
8. Burger D.M. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob. Agents Chemother. 1993, 37:1426-1432.
9. Niemi M. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 2003, 42:819-851.
10. Esposito S., D'Ambrosio L., Tadolini M., Schaaf H.S., Caminero Luna J., Marais B., Centis R., Dara M., Matteelli A., Blasi F., Migliori G.B. ERS/WHO tuberculosis consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur. Respir. J. 2014, 44:811-815.
11. Marisa K., Robin Mark W., Cindy H., Nicolaas Claudius Gey van P., Elizabeth Maria S., Borna M., Frederick Adriaan S., Mamisa C.-N., Ebrahim H., Gerrit C., Paul David van H., Thomas Calldo V., André Phillip T. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg. Infect. Dis. J. 2013, 19:449.
12. Raviglione M. XDR-TB: entering the post-antibiotic era?. Int. J. Tuberc. Lung Dis. 2006, 10:1185-1187.
13. Kumar K., Abubakar I. Clinical implications of the global multidrug-resistant tuberculosis epidemic. Clin. Med. 2015, 15:s37-s42.
14. Gler M.T., Skripconoka V., Sanchez-Garavito E., Xiao H., Cabrera-Rivero J.L., Vargas-Vasquez D.E., Gao M., Awad M., Park S.K., Shim T.S., Suh G.Y., Danilovits M., Ogata H., Kurve A., Chang J., Suzuki K., Tupasi T., Koh W.J., Seaworth B., Geiter L.J., Wells C.D. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 2012, 366:2151-2160.
15. Cohen J. Approval of novel TB drug celebrated-with restraint. Science 2013, 339:130.
16. Ryan N., Lo J. Delamanid: first global approval. Drugs 2014, 74:1041-1045.
17. Cohen K.A., Bishai W.R., Pym A.S. Molecular basis of drug resistance in Mycobacterium tuberculosis. Microbiol. Spectr. 2014, 2.
18. Palomino J., Martin A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics 2014, 3:317.
19. Fonseca J.D., Knight G.M., McHugh T.D. The complex evolution of antibiotic resistance in Mycobacterium tuberculosis. Int. J. Infect. Dis. 2015, 32:94-100.
20. Gagneux S., Long C.D., Small P.M., Van T., Schoolnik G.K., Bohannan B.J. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006, 312:1944-1946.
21. Casali N., Nikolayevskyy V., Balabanova Y., Harris S.R., Ignatyeva O., Kontsevaya I., Corander J., Bryant J., Parkhill J., Nejentsev S., Horstmann R.D., Brown T., Drobniewski F. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat. Genet. 2014, 46:279-286.
22. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 2014, 12:159-167.
23. Koul A., Dendouga N., Vergauwen K., Molenberghs B., Vranckx L., Willebrords R., Ristic Z., Lill H., Dorange I., Guillemont J., Bald D., Andries K. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 2007, 3:323-324.
24. Diacon A.H., Pym A., Grobusch M., Patientia R., Rustomjee R., Page-Shipp L., Pistorius C., Krause R., Bogoshi M., Churchyard G., Venter A., Allen J., Palomino J.C., De Marez T., van Heeswijk R.P., Lounis N., Meyvisch P., Verbeeck J., Parys W., de Beule K., Andries K., Mc Neeley D.F. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 2009, 360:2397-2405.
25. Andries K., Verhasselt P., Guillemont J., Göhlmann H.W.H., Neefs J.-M., Winkler H., Van Gestel J., Timmerman P., Zhu M., Lee E., Williams P., de Chaffoy D., Huitric E., Hoffner S., Cambau E., Truffot-Pernot C., Lounis N., Jarlier V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
26. Watanabe S., Zimmermann M., Goodwin M.B., Sauer U., Barry C.E., Boshoff H.I. Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog. 2011, 7.
27. Lounis N., Gevers T., Van Den Berg J., Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob. Agents Chemother. 2008, 52:3568-3572.
28. Preiss L., Langer J.D., Yildiz Ö., Eckhardt-Strelau L., Guillemont J.E.G., Koul A., Meier T. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci. Adv. 2015, 1.
29. Pethe K., Bifani P., Jang J., Kang S., Park S., Ahn S., Jiricek J., Jung J., Jeon H.K., Cechetto J., Christophe T., Lee H., Kempf M., Jackson M., Lenaerts A.J., Pham H., Jones V., Seo M.J., Kim Y.M., Seo M., Seo J.J., Park D., Ko Y., Choi I., Kim R., Kim S.Y., Lim S., Yim S.A., Nam J., Kang H., Kwon H., Oh C.T., Cho Y., Jang Y., Kim J., Chua A., Tan B.H., Nanjundappa M.B., Rao S.P., Barnes W.S., Wintjens R., Walker J.R., Alonso S., Lee S., Kim J., Oh S., Oh T., Nehrbass U., Han S.J., No Z., Lee J., Brodin P., Cho S.N., Nam K., Kim J. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 2013, 19:1157-1160.
30. Abrahams K.A., Cox J.A.G., Spivey V.L., Loman N.J., Pallen M.J., Constantinidou C., Fernández R., Alemparte C., Remuiñán M.J., Barros D., Ballell L., Besra G.S. Identification of novel Imidazo[1,2-a]pyridine inhibitors targetingM. tuberculosis QcrB. PLoS ONE 2012, 7.
31. Moraski G.C., Miller P.A., Bailey M.A., Ollinger J., Parish T., Boshoff H.I., Cho S., Anderson J.R., Mulugeta S., Franzblau S.G., Miller M.J. Putting tuberculosis (TB) to rest: transformation of the Sleep Aid, Ambien, and "Anagrams" generated potent antituberculosis agents. ACS Infect. Dis. 2015, 1:85-90.
32. Lee R.E., Mikusova K., Brennan P.J., Besra G.S. Synthesis of the arabinose donor.beta.-D-arabinofuranosyl-1-monophosphoryldecaprenol, development of a basic arabinosyl-transferase assay, and identification of ethambutol as an arabinosyl transferase inhibitor. J. Am. Chem. Soc. 1995, 117:11829-11832.
33. Wolucka B.A. Biosynthesis of D-arabinose in mycobacteria-a novel bacterial pathway with implications for antimycobacterial therapy. FEBS J. 2008, 275:2691-2711.
34. Goldman R.C. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?. Tuberculosis (Edinb.) 2013, 93:569-588.
35. Riccardi G., Pasca M., Chiarelli L., Manina G., Mattevi A., Binda C. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. Appl. Microbiol. Biotechnol. 2013, 97:8841-8848.
36. Makarov V., Manina G., Mikusova K., Möllmann U., Ryabova O., Saint-Joanis B., Dhar N., Pasca M.R., Buroni S., Lucarelli A.P., Milano A., De Rossi E., Belanova M., Bobovska A., Dianiskova P., Kordulakova J., Sala C., Fullam E., Schneider P., McKinney J.D., Brodin P., Christophe T., Waddell S., Butcher P., Albrethsen J., Rosenkrands I., Brosch R., Nandi V., Bharath S., Gaonkar S., Shandil R.K., Balasubramanian V., Balganesh T., Tyagi S., Grosset J., Riccardi G., Cole S.T. Benzothiazinones kill Mycobacterium tuberculosis by blocking Arabinan synthesis. Science 2009, 324:801-804.
37. Makarov V., Lechartier B., Zhang M., Neres J., van der Sar A.M., Raadsen S.A., Hartkoorn R.C., Ryabova O.B., Vocat A., Decosterd L.A., Widmer N., Buclin T., Bitter W., Andries K., Pojer F., Dyson P.J., Cole S.T. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol. Med. 2014, 6:372-383.
38. Trefzer C., Rengifo-Gonzalez M., Hinner M.J., Schneider P., Makarov V., Cole S.T., Johnsson K. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-d-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. Chem. Soc. 2010, 132:13663-13665.
39. Matsumoto M., Hashizume H., Tomishige T., Kawasaki M., Tsubouchi H., Sasaki H., Shimokawa Y., Komatsu M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006, 3.
40. Shirude P.S., Shandil R., Sadler C., Naik M., Hosagrahara V., Hameed S., Shinde V., Bathula C., Humnabadkar V., Kumar N., Reddy J., Panduga V., Sharma S., Ambady A., Hegde N., Whiteaker J., McLaughlin R.E., Gardner H., Madhavapeddi P., Ramachandran V., Kaur P., Narayan A., Guptha S., Awasthy D., Narayan C., Mahadevaswamy J., Vishwas K.G., Ahuja V., Srivastava A., Prabhakar K.R., Bharath S., Kale R., Ramaiah M., Choudhury N.R., Sambandamurthy V.K., Solapure S., Iyer P.S., Narayanan S., Chatterji M. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. J. Med. Chem. 2013, 56:9701-9708.
41. Shirude P.S., Shandil R.K., Manjunatha M.R., Sadler C., Panda M., Panduga V., Reddy J., Saralaya R., Nanduri R., Ambady A., Ravishankar S., Sambandamurthy V.K., Humnabadkar V., Jena L.K., Suresh R.S., Srivastava A., Prabhakar K.R., Whiteaker J., McLaughlin R.E., Sharma S., Cooper C.B., Mdluli K., Butler S., Iyer P.S., Narayanan S., Chatterji M. Lead optimization of 1,4-azaindoles as antimycobacterial agents. J. Med. Chem. 2014, 57:5728-5737.
42. Donald P.R., Schaaf H.S. Old and new drugs for the treatment of tuberculosis in children. Paediatr. Respir. Rev. 2007, 8:134-141.
43. Wang F., Sambandan D., Halder R., Wang J., Batt S.M., Weinrick B., Ahmad I., Yang P., Zhang Y., Kim J., Hassani M., Huszar S., Trefzer C., Ma Z., Kaneko T., Mdluli K.E., Franzblau S., Chatterjee A.K., Johnsson K., Mikusova K., Besra G.S., Fütterer K., Robbins S.H., Barnes S.W., Walker J.R., Jacobs W.R., Schultz P.G. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc. Natl. Acad. Sci. 2013, 110:E2510-E2517.
44. Muttucumaru D.G.N., Roberts G., Hinds J., Stabler R.A., Parish T. Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis 2004, 84:239-246.
45. Domenech P., Reed M.B., Barry C.E. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect. Immun. 2005, 73:3492-3501.
46. Lee R.E., Protopopova M., Crooks E., Slayden R.A., Terrot M., Barry C.E. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 2003, 5:172-187.
47. Biava M., Porretta G.C., Manetti F. New derivatives of BM212: A class of antimycobacterial compounds based on the pyrrole ring as a scaffold. Mini-Rev. Med. Chem. 2007, 7:65-78.
48. Li W., Upadhyay A., Fontes F.L., North E.J., Wang Y., Crans D.C., Grzegorzewicz A.E., Jones V., Franzblau S.G., Lee R.E., Crick D.C., Jackson M. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2014, 58:6413-6423.
49. Poce G., Bates R.H., Alfonso S., Cocozza M., Porretta G.C., Ballell L., Rullas J., Ortega F., De Logu A., Agus E., La Rosa V., Pasca M.R., De Rossi E., Wae B., Franzblau S.G., Manetti F., Botta M., Biava M. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLoS One 2013, 8.
50. Li K., Schurig-Briccio L.A., Feng X., Upadhyay A., Pujari V., Lechartier B., Fontes F.L., Yang H., Rao G., Zhu W., Gulati A., No J.H., Cintra G., Bogue S., Liu Y.-L., Molohon K., Orlean P., Mitchell D.A., Freitas-Junior L., Ren F., Sun H., Jiang T., Li Y., Guo R.-T., Cole S.T., Gennis R.B., Crick D.C., Oldfield E. Multitarget drug discovery for tuberculosis and other infectious diseases. J. Med. Chem. 2014, 57:3126-3139.
51. Rao S.P., Lakshminarayana S.B., Kondreddi R.R., Herve M., Camacho L.R., Bifani P., Kalapala S.K., Jiricek J., Ma N.L., Tan B.H., Ng S.H., Nanjundappa M., Ravindran S., Seah P.G., Thayalan P., Lim S.H., Lee B.H., Goh A., Barnes W.S., Chen Z., Gagaring K., Chatterjee A.K., Pethe K., Kuhen K., Walker J., Feng G., Babu S., Zhang L., Blasco F., Beer D., Weaver M., Dartois V., Glynne R., Dick T., Smith P.W., Diagana T.T., Manjunatha U.H. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci. Transl. Med. 2013, 5. (214ra168).
52. Lun S., Guo H., Onajole O.K., Pieroni M., Gunosewoyo H., Chen G., Tipparaju S.K., Ammerman N.C., Kozikowski A.P., Bishai W.R. Indoleamides are active against drug-resistant Mycobacterium tuberculosis. Nat. Commun. 2013, 4.
53. Wright H.T., Reynolds K.A. Antibacterial targets in fatty acid biosynthesis. Curr. Opin. Microbiol. 2007, 10:447-453.
54. Zhang Y.-M., White S.W., Rock C.O. Inhibiting bacterial fatty acid synthesis. J. Biol. Chem. 2006, 281:17541-17544.
55. Li H.-J., Lai C.-T., Pan P., Yu W., Liu N., Bommineni G.R., Garcia-Diaz M., Simmerling C., Tonge P.J. A structural and energetic model for the slow-onset inhibition of the Mycobacterium tuberculosis Enoyl-ACP reductase InhA. ACS Chem. Biol. 2014, 9:986-993.
56. Rawat R., Whitty A., Tonge P.J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl. Acad. Sci. 2003, 100:13881-13886.
57. Lai C.-T., Li H.-J., Yu W., Shah S., Bommineni G.R., Perrone V., Garcia-Diaz M., Tonge P.J., Simmerling C. Rational modulation of the induced-fit conformational change for slow-onset inhibition in Mycobacterium tuberculosis InhA. Biochemistry 2015, 54:4683-4691.
58. Lu H., Tonge P.J. Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 2010, 14:467-474.
59. Tummino P.J., Copeland R.A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008, 47:5481-5492.
60. Copeland R.A., Pompliano D.L., Meek T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 2006, 5:730-739.
61. Lu H., England K., am Ende C., Truglio J.J., Luckner S., Reddy B.G., Marlenee N.L., Knudson S.E., Knudson D.L., Bowen R.A., Kisker C., Slayden R.A., Tonge P.J. Slow-onset inhibition of the fabi enoyl reductase from Francisella tularensis: residence time and in vivo activity. ACS Chem. Biol. 2009, 4:221-231.
62. Kaplan N., Albert M., Awrey D., Bardouniotis E., Berman J., Clarke T., Dorsey M., Hafkin B., Ramnauth J., Romanov V., Schmid M.B., Thalakada R., Yethon J., Pauls H.W. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob. Agents Chemother. 2012, 56:5865-5874.
63. Escaich S., Prouvensier L., Saccomani M., Durant L., Oxoby M., Gerusz V., Moreau F., Vongsouthi V., Maher K., Morrissey I., Soulama-Mouze C. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob. Agents Chemother. 2011, 55:4692-4697.
64. Šink R., Sosič I., Živec M., Fernandez-Menendez R., Turk S., Pajk S., Alvarez-Gomez D., Lopez-Roman E.M., Gonzales-Cortez C., Rullas-Triconado J., Angulo-Barturen I., Barros D., Ballell-Pages L., Young R.J., Encinas L., Gobec S. Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis. J. Med. Chem. 2015, 58:613-624.
65. Shirude P.S., Madhavapeddi P., Naik M., Murugan K., Shinde V., Nandishaiah R., Bhat J., Kumar A., Hameed S., Holdgate G., Davies G., McMiken H., Hegde N., Ambady A., Venkatraman J., Panda M., Bandodkar B., Sambandamurthy V.K., Read J.A. Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis. J. Med. Chem. 2013, 56:8533-8542.
66. Manjunatha U.H., Rao S.P.S., Kondreddi R.R., Noble C.G., Camacho L.R., Tan B.H., Ng S.H., Ng P.S., Ma N.L., Lakshminarayana S.B., Herve M., Barnes S.W., Yu W., Kuhen K., Blasco F., Beer D., Walker J.R., Tonge P.J., Glynne R., Smith P.W., Diagana T.T. Direct inhibitors of InhA are active against Mycobacterium tuberculosis. Sci. Transl. Med. 2015, 7. (269ra263).
67. Keener A.B. Oldie but goodie: repurposing penicillin for tuberculosis. Nat. Med. 2014, 20:976-978.
68. Nadler J.P., Berger J., Nord J.A., Cofsky R., Saxena M. AMoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991, 99:1025-1026.
69. Dooley K.E., Obuku E.A., Durakovic N., Belitsky V., Mitnick C., Nuermberger E.L. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?. J. Infect. Dis. 2013, 207:1352-1358.
70. Dubée V., Triboulet S., Mainardi J.-L., Ethève-Quelquejeu M., Gutmann L., Marie A., Dubost L., Hugonnet J.-E., Arthur M. Inactivation of Mycobacterium tuberculosis l,d-Transpeptidase LdtMt1 by carbapenems and cephalosporins. Antimicrob. Agents Chemother. 2012, 56:4189-4195.
71. Wivagg C.N., Bhattacharyya R.P., Hung D.T. Mechanisms of [beta]-lactam killing and resistance in the context of Mycobacterium tuberculosis. J. Antibiot. 2014, 67:645-654.
72. De Lorenzo S., Alffenaar J.W., Sotgiu G., Centis R., D'Ambrosio L., Tiberi S., Bolhuis M.S., van Altena R., Viggiani P., Piana A., Spanevello A., Migliori G.B. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur. Respir. J. 2013, 41:1386-1392.
73. Chambers H.F., Turner J., Schecter G.F., Kawamura M., Hopewell P.C. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother. 2005, 49:2816-2821.
74. Hugonnet J.-E., Tremblay L.W., Boshoff H.I., Barry C.E., Blanchard J.S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009, 323:1215-1218.
75. Payen M.C., De Wit S., Martin C., Sergysels R., Muylle I., Van Laethem Y., Clumeck N. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2012, 16:558-560.
76. Hoagland D., Zhao Y., Lee R. Advances in drug discovery and development for pediatric tuberculosis. Mini-Rev. Med. Chem. 2016, 16:481-497.
77. Milazzo I., Blandino G., Caccamo F., Musumeci R., Nicoletti G., Speciale A. Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates. J. Antimicrob. Chemother. 2003, 51:721-725.
78. Schurek K.N., Wiebe R., Karlowsky J.A., Rubinstein E., Hoban D.J., Zhanel G.G. Faropenem: review of a new oral penem. Expert Rev. Anti-Infect. Ther. 2007, 5:185-198.
79. Dhar N., Dubée V., Ballell L., Cuinet G., Hugonnet J.-E., Signorino-Gelo F., Barros D., Arthur M., McKinney J.D. Rapid cytolysis of Mycobacterium tuberculosis by Faropenem, an orally bioavailable β-lactam antibiotic. Antimicrob. Agents Chemother. 2015, 59:1308-1319.
80. Lee M., Lee J., Carroll M.W., Choi H., Min S., Song T., Via L.E., Goldfeder L.C., Kang E., Jin B., Park H., Kwak H., Kim H., Jeon H.S., Jeong I., Joh J.S., Chen R.Y., Olivier K.N., Shaw P.A., Follmann D., Song S.D., Lee J.K., Lee D., Kim C.T., Dartois V., Park S.K., Cho S.N., Barry C.E. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 2012, 367:1508-1518.
81. Ashtekar D.R., Costa-Periera R., Shrinivasan T., Iyyer R., Vishvanathan N., Rittel W. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis. 1991, 14:465-471.
82. Rose P.C., Hallbauer U.M., Seddon J.A., Hesseling A.C., Schaaf H.S. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int. J. Tuberc. Lung Dis. 2012, 16:1588-1593.
83. Anger H.A., Dworkin F., Sharma S., Munsiff S.S., Nilsen D.M., Ahuja S.D. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J. Antimicrob. Chemother. 2010, 65:775-783.
84. Garcia-Prats A.J., Rose P.C., Hesseling A.C., Schaaf H.S. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. Tuberculosis (Edinb.) 2014, 94:93-104.
85. Balasubramanian V., Solapure S., Iyer H., Ghosh A., Sharma S., Kaur P., Deepthi R., Subbulakshmi V., Ramya V., Ramachandran V., Balganesh M., Wright L., Melnick D., Butler S.L., Sambandamurthy V.K. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob. Agents Chemother. 2014, 58:495-502.
86. Bruhn D.F., Scherman M.S., Liu J., Scherbakov D., Meibohm B., Böttger E.C., Lenaerts A.J., Lee R.E. In vitro and in vivo evaluation of synergism between anti-tubercular spectinamides and non-classical tuberculosis antibiotics. Sci. Rep. 2015, 5:13985.
87. Rock F.L., Mao W., Yaremchuk A., Tukalo M., Crépin T., Zhou H., Zhang Y.-K., Hernandez V., Akama T., Baker S.J., Plattner J.J., Shapiro L., Martinis S.A., Benkovic S.J., Cusack S., Alley M.R.K. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007, 316:1759-1761.
88. Hu Q.-H., Liu R.-J., Fang Z.-P., Zhang J., Ding Y.-Y., Tan M., Wang M., Pan W., Zhou H.-C., Wang E.-D. Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase. Sci. Rep. 2013, 3.
89. Hernandez V., Crépin T., Palencia A., Cusack S., Akama T., Baker S.J., Bu W., Feng L., Freund Y.R., Liu L., Meewan M., Mohan M., Mao W., Rock F.L., Sexton H., Sheoran A., Zhang Y., Zhang Y.-K., Zhou Y., Nieman J.A., Anugula M.R., Keramane E.M., Savariraj K., Reddy D.S., Sharma R., Subedi R., Singh R., O'Leary A., Simon N.L., De Marsh P.L., Mushtaq S., Warner M., Livermore D.M., Alley M.R.K., Plattner J.J. Discovery of a novel class of boron-based antibacterials with activity against Gram-negative bacteria. Antimicrob. Agents Chemother. 2013, 57:1394-1403.
90. Davies J. Where have all the antibiotics gone?. Can. J. Infect. Dis. Med. Microbiol. 2006, 17:287-290.
91. Borovinskaya M.A., Shoji S., Holton J.M., Fredrick K., Cate J.H.D. A steric block in translation caused by the antibiotic spectinomycin. ACS Chem. Biol. 2007, 2:545-552.
92. Kehrenberg C., Schwarz S. Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida. Antimicrob. Agents Chemother. 2007, 51:2244-2246.
93. Lee R.E., Hurdle J.G., Liu J., Bruhn D.F., Matt T., Scherman M.S., Vaddady P.K., Zheng Z., Qi J., Akbergenov R., Das S., Madhura D.B., Rathi C., Trivedi A., Villellas C., Lee R.B., Rakesh, Waidyarachchi S.L., Sun D., McNeil M.R., Ainsa J.A., Boshoff H.I., Gonzalez-Juarrero M., Meibohm B., Bottger E.C., Lenaerts A.J. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat. Med. 2014, 20:152-158.
94. Noufflard-Guy-Loe H., Berteaux S. Experimental antituberculous action of a new antibiotic: RP 11,072. Rev. Tuberc. Pneumol. 1965, 29:301-326.
95. Terlain B., Thomas J.P. Structure of griselimycin, polypeptide antibiotic extracted from streptomyces cultures. II. Structure of griselimycin. Bull. Soc. Chim. Fr. 1971, 6:2357-2362.
96. Kling A., Lukat P., Almeida D.V., Bauer A., Fontaine E., Sordello S., Zaburannyi N., Herrmann J., Wenzel S.C., König C., Ammerman N.C., Barrio M.B., Borchers K., Bordon-Pallier F., Brönstrup M., Courtemanche G., Gerlitz M., Geslin M., Hammann P., Heinz D.W., Hoffmann H., Klieber S., Kohlmann M., Kurz M., Lair C., Matter H., Nuermberger E., Tyagi S., Fraisse L., Grosset J.H., Lagrange S., Müller R. Targeting DnaN for tuberculosis therapy using novel griselimycins. Science 2015, 348:1106-1112.
97. Reddy V.M., Einck L., Nacy C.A. In vitro antimycobacterial activities of Capuramycin Analogues. Antimicrob. Agents Chemother. 2008, 52:719-721.
98. Nikonenko B.V., Reddy V.M., Protopopova M., Bogatcheva E., Einck L., Nacy C.A. Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2009, 53:3138-3139.
99. Nikonenko B., Reddy V.M., Bogatcheva E., Protopopova M., Einck L., Nacy C.A. Therapeutic efficacy of SQ641-NE against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2014, 58:587-589.
100. Salomon J.J., Galeron P., Schulte N., Morow P.R., Severynse-Stevens D., Huwer H., Daum N., Lehr C.-M., Hickey A.J., Ehrhardt C. Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis. Ther. Deliv. 2013, 4:915-923.
101. Hartkoorn R.C., Sala C., Neres J., Pojer F., Magnet S., Mukherjee R., Uplekar S., Boy-Röttger S., Altmann K.-H., Cole S.T. Towards a new tuberculosis drug: pyridomycin - nature's isoniazid. EMBO Mol. Med. 2012, 4:1032-1042.
102. Hartkoorn R.C., Pojer F., Read J.A., Gingell H., Neres J., Horlacher O.P., Altmann K.-H., Cole S.T. Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA. Nat. Chem. Biol. 2014, 10:96-98.
103. Zumla A.I., Gillespie S.H., Hoelscher M., Philips P.P.J., Cole S.T., Abubakar I., McHugh T.D., Schito M., Maeurer M., Nunn A.J. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect. Dis. 2014, 14:327-340.
104. Riccardi G., Pasca M.R. Trends in discovery of new drugs for tuberculosis therapy. J. Antibiot. 2014, 67:655-659.
105. Mdluli K., Kaneko T., Upton A. The tuberculosis drug discovery and development pipeline and emerging drug targets. Cold Spring Harb. Perspect. Med. 2015, 5.
106. Ioerger T.R., O'Malley T., Liao R., Guinn K.M., Hickey M.J., Mohaideen N., Murphy K.C., Boshoff H.I.M., Mizrahi V., Rubin E.J., Sassetti C.M., Barry C.E., Sherman D.R., Parish T., Sacchettini J.C. Identification of new drug targets and resistance mechanisms inMycobacterium tuberculosis. PLoS ONE 2013, 8.
107. Schubert O.T., Mouritsen J., Ludwig C., Röst H.L., Rosenberger G., Arthur P.K., Claassen M., Campbell D.S., Sun Z., Farrah T., Gengenbacher M., Maiolica A., Kaufmann S.H.E., Moritz R.L., Aebersold R. The Mtb Proteome Library: a resource of assays to quantify the complete proteome of Mycobacterium tuberculosis. Cell Host Microbe 2013, 13:602-612.
108. Cohen K.A., Abeel T., McGuire A.M., Desjardins C.A., Munsamy V., Shea T.P., Walker B.J., Bantubani N., Almeida D.V., Alvarado L., Chapman S., Mvelase N.R., Duffy E.Y., Fitzgerald M.G., Govender P., Gujja S., Hamilton S., Howarth C., Larimer J.D., Maharaj K., Pearson M.D., Priest M.E., Zeng Q., Padayatchi N., Grosset J., Young S.K., Wortman J., Mlisana K.P., O'Donnell M.R., Birren B.W., Bishai W.R., Pym A.S., Earl A.M. Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa. Int. J. Mycobacteriol. 2015, 4(Suppl. 1):24-25.
109. Kuan C.S., Chan C.L., Yew S.M., Toh Y.F., Khoo J.-S., Chong J., Lee K.W., Tan Y.-C., Yee W.-Y., Ngeow Y.F., Ng K.P. Genome analysis of the first extensively drug-resistant (XDR) Mycobacterium tuberculosis in Malaysia provides insights into the genetic basis of its biology and drug resistance. PLoS One 2015, 10.
110. Schnappinger D., O'Brien K., Ehrt S. Construction of conditional knockdown mutants in mycobacteria. Mycobacteria Protocols 2015, 151-175. Springer, New York. T. Parish, D.M. Roberts (Eds.).
111. Woong Park S., Klotzsche M., Wilson D.J., Boshoff H.I., Eoh H., Manjunatha U., Blumenthal A., Rhee K., Barry C.E., Aldrich C.C., Ehrt S., Schnappinger D. Evaluating the sensitivity ofMycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog. 2011, 7.
112. Gold B., Warrier T., Nathan C. A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis. Mycobacteria Protocols 2015, 293-315. Springer, New York. T. Parish, D.M. Roberts (Eds.).
113. VanderVen B.C., Fahey R.J., Lee W., Liu Y., Abramovitch R.B., Memmott C., Crowe A.M., Eltis L.D., Perola E., Deininger D.D., Wang T., Locher C.P., Russell D.G. Novel inhibitors of cholesterol degradation inMycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment. PLoS Pathog. 2015, 11.
114. Prideaux B., Via L.E., Zimmerman M.D., Eum S., Sarathy J., O'Brien P., Chen C., Kaya F., Weiner D.M., Chen P.Y., Song T., Lee M., Shim T.S., Cho J.S., Kim W., Cho S.N., Olivier K.N., Barry C.E., Dartois V. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat. Med. 2015, 21:1223-1227.
115. Gillespie S.H., Crook A.M., McHugh T.D., Mendel C.M., Meredith S.K., Murray S.R., Pappas F., Phillips P.P.J., Nunn A.J. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 2014, 371:1577-1587.
116. Kjellsson M.C., Via L.E., Goh A., Weiner D., Low K.M., Kern S., Pillai G., Barry C.E., Dartois V. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 2012, 56:446-457.
117. Michot J.-M., Seral C., Van Bambeke F., Mingeot-Leclercq M.-P., Tulkens P.M. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob. Agents Chemother. 2005, 49:2429-2437.
118. Barclay W.R., Ebert R.H., Le Roy G.V., Manthei R.W., Roth L.J. Distribution and excretion of radioactive isoniazid in tuberculous patients. J. Am. Med. Assoc. 1953, 151:1384-1388.
119. Canetti G., Parrot R., Porven G., Le Lirzin M. Rifomycin levels in the lung and tuberculous lesions in man. Acta Tuberc. Pneumol. Belg. 1969, 60:315-322.
120. Ellard G.A., Humphries M.J., Allen B.W. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am. Rev. Respir. Dis. 1993, 148:650-655.
121. Ellard G.A., Humphries M.J., Gabriel M., Teoh R. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. Br. Med. J. (Clin. Res. Ed.) 1987, 294:284-285.
122. Prideaux B., Dartois V., Staab D., Weiner D.M., Goh A., Via L.E., Barry C.E., Stoeckli M. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal. Chem. 2011, 83:2112-2118.
123. Prideaux B., Stoeckli M. Mass spectrometry imaging for drug distribution studies. J. Proteome 2012, 75:4999-5013.
124. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S.V., Eiglmeier K., Gas S., Barry C.E., Tekaia F., Badcock K., Basham D., Brown D., Chillingworth T., Connor R., Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S., Hornsby T., Jagels K., Krogh A., McLean J., Moule S., Murphy L., Oliver K., Osborne J., Quail M.A., Rajandream M.A., Rogers J., Rutter S., Seeger K., Skelton J., Squares R., Squares S., Sulston J.E., Taylor K., Whitehead S., Barrell B.G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537-544.
125. Brown E.D., Wright G.D. New targets and screening approaches in antimicrobial drug discovery. Chem. Rev. 2005, 105:759-774.
126. Wunberg T., Hendrix M., Hillisch A., Lobell M., Meier H., Schmeck C., Wild H., Hinzen B. Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. Drug Discov. Today 2006, 11:175-180.
127. Elinder M., Geitmann M., Gossas T., Källblad P., Winquist J., Nordström H., Hämäläinen M., Danielson U.H. Experimental validation of a fragment library for lead discovery using SPR biosensor technology. J. Biomol. Screen. 2011, 16:15-25.
128. Brown J.R., North E.J., Hurdle J.G., Morisseau C., Scarborough J.S., Sun D., Kordulakova J., Scherman M.S., Jones V., Grzegorzewicz A., Crew R.M., Jackson M., McNeil M.R., Lee R.E. The structure-activity relationship of urea derivatives as anti-tuberculosis agents. Bioorg. Med. Chem. 2011, 19:5585-5595.
129. Keseru G.M., Makara G.M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discov. 2009, 8:203-212.
130. Lipinski C. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23:3-25.
131. Lipinski C. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
132. Maitra A., Bates S., Kolvekar T., Devarajan P.V., Guzman J.D., Bhakta S. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis. Int. J. Infect. Dis. 2015, 32:50-55.
133. Zhang D., Wang Y., Lu J., Pang Y. In vitro activity of β-lactams in combination with β-lactamase inhibitors against multidrug-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 2015, 60:393-399.
134. Hazra S., Xu H., Blanchard J.S. Tebipenem, a new carbapenem antibiotic, Is a Slow Substrate That Inhibits the β-Lactamase from Mycobacterium tuberculosis. Biochemistry 2014, 53:3671-3678.